NCT02554396已完成2 期
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia
LENZ Therapeutics, Inc1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- binocular assessment of uncorrected near visual acuity
研究概览
简要总结
This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision acuity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 45 Years 至 59 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •be 45-59 years of age of either sex and any race or ethnicity;
- •be able and willing to provide written informed consent and sign HIPAA form prior to any study procedure being performed;
- •be able and willing to follow all instructions and attend all study visits;
- •have a negative urine pregnancy test at Visit 1, if female of childbearing potential (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 months after last menses]) and must use adequate birth control throughout the study period. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control;
- •be an early to moderate presbyope
- •be able and willing to avoid all disallowed medication(s) for the appropriate washout period and during the study without significant risk to the subject (see exclusion 15).
排除标准
- •have known contraindications or sensitivity to the use of any of the study medications(s) or their components;
- •have an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g. moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye. Mild dry eye controlled with artificial tears and mild blepharitis controlled with lid scrubs is allowed;
- •have had surgical intervention (ocular or systemic) within 6 months prior to Visit 1, or planned surgical intervention within 30 days thereafter;
- •have had refractive surgery in the past;
- •have dry eye history defined as either current use of Restasis®, past history of insertion of punctual plugs, or daily use of artificial tears more than one drop per day;
- •have a known history of retinal detachment, diabetic retinopathy, or progressive retinal disease;
- •have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg, or be on any type of intraocular hypertension or any type of glaucoma topical treatment at Visit 1;
- •have red-green color blindness confirmed by Ishihara test during baseline procedures;
- •have an inability or refuse to discontinue contact lens wear 7 days prior to the study visit and during the study visit;
- •have used an investigational drug or device within 30 days of starting the study or be concurrently enrolled in another investigational drug or device study;
- •be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy; tests positive to a urine pregnancy test at Visit 1; or refuses to use an adequate method of contraception for the duration of the study;
- •have a condition or a situation, which in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation, including but not limited to unstable: cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease;
- •use any of the following disallowed medications during the 2 weeks (14 days) prior to Visit 1 and during the study:
- •narcotic (opiate class) pain medication (e.g. codeine, oxycontin, Vicodin®, Tramadol®)
- •bladder medication (e.g. urecholine, bethanechol®)
- •antipsychotics
- •antidepressants
- •anticholinergics (e.g. atropine, belladonna, benztropine, dicyclomine, donepezil, hyoscyamine, propantheline, scopolamine, trihexphenidyl
- •dry mouth (e.g. salagen®), Evoxac®)
- •antihistamines or decongestants
- •artificial tear use of more than 1 drop per day
- •diagnostic medications required by the protocol are allowed;
- •report of recreational drug use (e.g. marijuana, methadone, heroin, cocaine).
研究组 & 干预措施
PRX-100
Experimental
PRX-100 ophthalmic solution
干预措施: PRX-100 (Drug)
Placebo
Placebo Comparator
saline solution
干预措施: Placebo (Drug)
结局指标
主要结局
binocular assessment of uncorrected near visual acuity
时间窗: day 1
次要结局
- pupil diameter(day 1)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic ConjunctivitisAllergic ConjunctivitisNCT05265910Andover Research Eye Institute58
已完成
2 期
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)Atopic AsthmaNCT04728711Aldeyra Therapeutics, Inc.8
终止
2 期
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)Cocaine UseCocaine IntoxicationCocaine ToxicityCocaine AbuseCocaine Adverse ReactionNCT06045793Tonix Pharmaceuticals, Inc.3
撤回
1 期
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ LymphomaT-Cell Acute Lymphocytic LeukemiaNCT05909527Guangzhou Bio-gene Technology Co., Ltd30
招募中
不适用
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRelapsed/Refractory Multiple MyelomaNCT06515262920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10